Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Accumulated Expenses (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Other Accumulated Expenses for 7 consecutive years, with $105000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $105000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $105000.0, a N/A change, with the full-year FY2024 number at $650000.0, changed N/A from a year prior.
  • Other Accumulated Expenses was $105000.0 for Q3 2025 at Whitehawk Therapeutics, down from $114000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.5 million in Q3 2021 to a low of $10805.0 in Q2 2021.
  • A 4-year average of $450804.8 and a median of $305000.0 in 2021 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 6976.32% in 2021; the steepest drop was 63.88% in 2021.
  • Whitehawk Therapeutics' Other Accumulated Expenses stood at $496000.0 in 2021, then skyrocketed by 34.68% to $668000.0 in 2022, then dropped by 2.69% to $650000.0 in 2024, then crashed by 83.85% to $105000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Other Accumulated Expenses are $105000.0 (Q3 2025), $114000.0 (Q2 2025), and $650000.0 (Q4 2024).